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ABSTRACT: As members of the Lewy Body
Dementia Association Scientific Advisory Council, we
aim to address some of the issues raised in the article
titled “Time to Redefine PD? Introductory Statement of
the MDS Task Force on the Definition of Parkinson’s
Disease.” In particular, we suggest that the 1-year rule
distinguishing Parkinson’s disease dementia from
dementia with Lewy bodies is worth maintaining
because it serves an important purpose in clinical prac-
tice and clinical and basic science research and when
helping the lay community understand the complexity
of these different clinical phenotypes. Furthermore, we
believe that adding an additional diagnostic label, “PD
(dementia with Lewy bodies subtype),” will confuse
rather than clarify the distinction between dementia with
Lewy bodies and PD or PD dementia, and will not
improve management or expedite therapeutic develop-
ment. We present arguments supporting our conten-
tions. VC 2016 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Inter-
national Parkinson and Movement Disorder Society.
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We read with interest the article by Berg and col-
leagues1 regarding possible changes to the definition of
PD as proposed by the International Parkinson and
Movement Disorders Society task force commissioned
to consider a redefinition of PD. Comments were
sought by the authors regarding the content of this
article. We aim to address some of the issues raised in
this article, particularly those relating to dementia and
the distinction between dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD).
We agree that there is clinical overlap between DLB
and PDD and concur that the 1-year time period may not
be the optimal method for diagnostic distinction, but we
also believe that the rule serves a useful purpose for clini-
cal practice and research studies and that its dismissal
would be both premature and problematic.We argue that
insufficient new evidence has been presented to justify a
modification to the diagnostic criteria for PDD and DLB
at this time. We also believe that adding an additional
diagnostic label, “PD (DLB subtype),” will confuse rather
than clarify the situation and will not improve manage-
ment or expedite therapeutic development.
Addressing the “Challenging the
Status Quo” Comments
Relevant challenges to redefine PD from the manu-
script are restated in italics below, with our responses
stated beneath each challenge.
Similar neuropsychological findings, with predomi-
nant visuoperceptual impairment, improvement of
memory with cueing, and so on.
We concur that once the dementia is diagnosed, visual
perceptual impairment, attention difficulty, and slowed
reaction time occur in both DLB and PDD.2,3 However,
the comorbid presence of Alzheimer’s disease (AD)
pathology is not uncommon in DLB and has been shown
to contribute to greater verbal memory impairment.4 In
addition, it is not known whether PDD and DLB differ
cognitively in the predementia (ie, mild cognitive impair-
ment [MCI]) stage, because the cognitive profile for the
MCI of DLB has yet to be firmly established.5 One study
found more severe cognitive deficits for patients in the
MCI stage of DLB when compared with PD-MCI.6 These
data raise questions about whether the early cognitive
impairments of DLB and PDD are truly indistinguishable.
Similar nonmotor profile, with olfactory loss, depres-
sion, autonomic dysfunction, and sleep disorders in both.
Although these nonmotor features are indeed com-
mon to PD, PDD, and DLB, their frequency, phenom-
enology, prominence in the clinical picture, and timing
and evolution may differ between PD, PDD, and DLB.
Lumping nonmotor symptoms as part of the PD
umbrella may deter further investigation into why
these differences may emerge and what unique role
they may play for DLB and other synucleinopathies.
Similar imaging, with overlapping patterns of corti-
cal atrophy, glucose utilization, neurotransmitter
changes, and diffusion tensor imaging.
As the authors acknowledged, amyloid deposition
imaged with positron emission tomography is higher
in DLB when compared with PD and PDD, and other
group-level differences in neuroimaging parameters
exist, including more gray matter atrophy on structur-
al MRI in DLB when compared with PDD.7,8 These
findings therefore underscore some key differences
between DLB and PDD on imaging.
Similar prodromal stage: For example, patients with
idiopathic RBD develop both syndromes, with little
difference in clinical evolution patterns.
Rapid eye movement sleep behavior disorder (RBD)
clearly can be an early manifestation of Lewy body dis-
ease, which eventually evolves into PD or DLB, and
many patients with PD and DLB have features of RBD
occurring years, or even decades, prior to the onset of
parkinsonism cognitive or psychiatric features.9 The
presence of RBD improves the diagnostic validity of the
current DLB criteria.10 However, there is insufficient
data to substantiate the claim that there is little differ-
ence in patterns of clinical evolution between DLB and
PDD in those with a prodromal history of RBD.
Similar genetics: For example, family members with
alpha-synuclein duplication or triplications as well as
glucocerebrosidase (GBA) mutations can present with
either condition.
Some of the most compelling evidence to maintain a
distinction between PDD and DLB comes from recent
studies that have uncovered some genetic differences
between them. Specifically, single nucleotide polymor-
phisms in the gene encoding mitochondrial transcription
factor A were found to be associated with PDD and not
DLB.11 Also, the apolipoprotein e E4 allele frequency was
higher in pure DLB (ie, without concomitant AD patholo-
gy) than in PDD.12 Furthermore, although GBA muta-
tions are reported in both DLB and PD, pure DLB has an
intermediate mutation frequency between AD and PD.13
A recent genomewide study of DLB also demonstrated
different genetic risk factors when comparedwith PD.14
Addressing the “Defense of the
Status Quo” Comments
Although patients with DLB and PDD look similar
at end stage, the course can be extremely different.
The most agreed on and empirically demonstrated
clinical difference between DLB and PDD pertains to
clinical course in the context of the temporal onset of
dementia and motor signs (ie, the 1-year rule). This
has special relevance when considering the prodromal
and preclinical stages of these neurodegenerative con-
ditions. In these conditions, with both motor and cog-
nitive deficits, when parkinsonian motor signs are the
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initial clinical feature (PDD), the onset of dementia
develops an average of 6 years later.15,16 When
dementia is a presenting feature (as in DLB), the onset
of parkinsonism develops an average of 2 years lat-
er.10 Clinical and pathologic differences are associated
with a longer duration of parkinsonism relative to
dementia onset and include older age,17 later onset of
visual hallucinations,18 less severe cortical alpha-
synuclein pathology, lower plaque scores, and greater
cholinergic cortical deficits19 in PDD when compared
with DLB. Also, there is a difference in severity as
well as phenomenology of motor signs and response
to dopaminergic therapy between the typical patient
with PDD who has had many years of motor PD
when compared with the archetypal patient who fits
DLB criteria, whose duration of motor dysfunction is
less, severity is often milder, and response to dopami-
nergic therapy is often less robust.
Many Parkinsonian DLB Patients Would Not
Meet Criteria for Clinical PD
We agree with this statement and would add that in
DLB there is also a subset of patients who do not
have parkinsonism. These patients meet clinical crite-
ria for probable DLB and have pathologic confirma-
tion of Lewy body disease, but do not exhibit clear-
cut extrapyramidal signs during life.10 This is one
example of the phenotypic heterogeneity in DLB and
an important reason why the most common misdiag-
nosis of DLB continues to be AD.20 More work is
needed to better understand DLB without parkinson-
ism, and placing DLB under the umbrella of PD may
deter further investigation of the nonmotor and motor
features of DLB.
Addressing the “Moving Forward”
Comments
In the section titled “Moving Forward,” the authors
suggest that we consider omitting the 1-year rule and
propose using “PD (DLB subtype)” for those patients
who meet clinical criteria for DLB and then fulfill cri-
teria for PD while maintaining the diagnosis of DLB
for those who never fulfill criteria for PD. We believe
that there is insufficient evidence to support this
change currently, and adding an additional diagnostic
category will only confuse the distinction further.
We agree that the 1-year time period is arbitrary,
may not be optimal, and will almost certainly be mod-
ified in the future when the genetic underpinnings,
pathophysiologic mechanisms, and prodromal states
of these disorders are better understood. It is well
known that identifying a precise date of onset for
either parkinsonism or dementia is often impossible,
so that the difficulties posed by the hypothetical clini-
cal scenario proposed by the authors, with onset of
dementia at 10 months, is likely rare in routine clini-
cal practice and does not justify changing diagnostic
criteria at this time. Empirical data are needed to
determine whether the use of the 1-year cut-off has
benefit, or if a longer cut-off between the onset of par-
kinsonism and the development of dementia would be
a better demarcation of PDD from DLB. Although the
1-year rule may not be optimal, we argue that modify-
ing the diagnosis of a DLB patient by whether they
meet clinical criteria for PD would neither help
patients and caregivers understand the prognosis nor
serve to inform clinical practice, which was part of the
original rationale for this guideline.21,22 To reliably
distinguish parkinsonism from PD may be achievable
in a specialist movement disorder setting, but would
likely introduce significant variation across the wide
range of different clinical settings in which dementia
patients are assessed and diagnosed.
Implications for Diagnosis,
Evaluation, Medical Management,
and Social and Supportive Care
The diagnosis, evaluation, medical management, edu-
cation, and community resources for patients with
dementia and their families may be difficult to cover
comprehensively when viewed from the perspective that
PD (and thereby, by the task force’s implication, DLB)
is predominantly a movement disorder. Clinical evalua-
tion and the management of people with dementia raise
complex issues and have to be delivered by a diversity
of clinicians with very different levels of expertise.
Patients, families, and clinicians therefore require a
diagnostic system that is simple, has high face validity,
and is widely used. Two decades of concerted effort
by the international research community has crafted a
mutually agreed on approach to the diagnosis of PD,
PDD, PD-MCI, and DLB, and modification of this
approach should be clearly supported by empirical
data. It is precisely this collaborative stability that has
enabled both PDD and DLB to have entered DSM-523
and to have been assigned as a national research prior-
ity by the United States.24
Summary and Recommendations
We argue that the statements from the 2005 Con-
sensus Group on DLB continue to hold true.22 There-
fore, we propose the following:
 The 1-year rule distinguishing PDD from DLB is
worth maintaining because it serves an important
purpose in clinical practice and clinical and basic
science research and in helping the lay community
understand the complexity of these apparently
different clinical phenotypes. Modification of the
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1-year time period may be justified when the
genetic underpinnings, pathophysiologic mecha-
nisms, and prodromal states of these disorders are
better understood. Modifying the diagnosis of
patients who meet diagnostic criteria for DLB
based on whether they meet diagnostic criteria for
PD is unjustified at this time, and the addition of a
further diagnostic category, “PD (DLB subtype),”
is not necessary and is potentially confusing.
 Continued attention should be given to identify-
ing the mild or early manifestations of Lewy body
disease and characterizing the longitudinal clinical
and biomarker changes associated with evolving
Lewy body disease.
 Symptomatic and disease-modifying interventions
should be developed using pharmacologic and
nonpharmacologic modalities for the syndromes
associated with Lewy body disease.
 Both phenotypes should be included in clinical tri-
als of new therapies for Lewy body dementia (as
opposed to lumping them into 1 phenotype) until
more research improves knowledge about the dif-
ferences and similarities between PDD and DLB.
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